ReviewCureus2025
Renaming Medullary Cystic Kidney Disease: A Review of Semantic Nomenclature.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medullary cystic kidney disease (MCKD) was originally described and designated with this nomenclature based on the etiology and the related clinicopathological features recognized during the mid-20th century. The designation of the MCKD term has stemmed from a set of morphological features characterized by the presence of epithelial-lined cysts ranging in size from a few microns to 1 cm in diameter, primarily located at the corticomedullary junction of the kidney. However, this term does not adequately represent the expanding knowledge about the kidney condition it describes, including its genetically based etiopathogenesis and the related clinicopathological correlations. The need for a more patient-centered and specific terminology has been recognized by the medical community and has necessitated reviewing the MCKD nomenclature. The proposed renaming of the condition to autosomal dominant tubulointerstitial kidney disease aligns closely with the genetic and pathological foundations of the disease. This renaming aims not only to enhance awareness about this kidney condition but also to improve its diagnostic accuracy and treatment strategies. This article highlights the historical observations related to MCKD and underscores the importance of adopting a revised and precise terminology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.